Allogene Therapeutics (NASDAQ: ALLO) surged approximately 60% in premarket trading on April 14, 2026, with shares reaching $4.35 after closing at $2.72 on April 10, following interim data from its Phase 2 ALPHA3 trial showing a 41.6 percentage-point absolute difference in MRD cle